{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"Synonym","name":"talquetamab"},{"type":"USBrandName","name":"Talvey"},{"type":"Synonym","name":"humanized GPRC5D x CD3 DuoBody antibody JNJ-64407564"},{"type":"CodeName","name":"JNJ 64407564"},{"type":"Synonym","name":"GPRC5D x CD3 DuoBody antibody JNJ-64407564"},{"type":"CodeName","name":"JNJ64407564"},{"type":"Synonym","name":"GPRC5D/CD3 DuoBody antibody JNJ-64407564"},{"type":"Synonym","name":"anti-CD3/anti-GPRC5D bispecific monoclonal antibody JNJ-64407564"},{"type":"Synonym","name":"GPRC5D x CD3 bispecific antibody JNJ-64407564"},{"type":"CASRegistryName","name":"2226212-40-2"},{"type":"CodeName","name":"JNJ-64407564"}],"definition":{"html":"A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, talquetamab-tgvs binds to both CD3 on T cells and GPRC5D expressed on certain tumor cells. This results in the cross-linking of T cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against GPRC5D-expressing tumor cells. GPRC5D is overexpressed on certain tumors, such as multiple myeloma, while minimally expressed on normal, healthy cells, and plays a key role in tumor cell proliferation.","text":"A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, talquetamab-tgvs binds to both CD3 on T cells and GPRC5D expressed on certain tumor cells. This results in the cross-linking of T cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against GPRC5D-expressing tumor cells. GPRC5D is overexpressed on certain tumors, such as multiple myeloma, while minimally expressed on normal, healthy cells, and plays a key role in tumor cell proliferation."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/talquetamab-tgvs","text":"Talquetamab-tgvs"},"nciConceptId":"C171840","nciConceptName":"Talquetamab","termId":792477,"name":"talquetamab-tgvs","firstLetter":"t","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"talquetamab"}],"links":null}